SLU-PP-332
SLU-PP-332 scored 4.9 / 10 (βοΈ Neutral) on the BioHarmony scale as a Substance β Research Compound. Synthetic pan-ERR agonist that activates the same gene expression program triggered by aerobic exercise.
What It Is
Synthetic pan-ERR agonist that activates the same gene expression program triggered by aerobic exercise. Preclinical only β zero human trials.
Upside (3.03 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.5 | 0.875 | |
| Breadth of Benefits | 15% | 4.0 | 0.600 | |
| Evidence Quality | 25% | 2.0 | 0.500 | |
| Speed of Onset | 10% | 4.0 | 0.400 | |
| Durability | 10% | 2.0 | 0.200 | |
| Bioindividuality Upside | 15% | 3.0 | 0.450 | |
| Total | 3.025 |
Upside Rationale
Efficacy (3.5/5.0). Animal data is striking β 50% longer running endurance after 8 days of daily SLU-PP-332 injection in sedentary mice (Burris lab, Cell Rep Med 2023). Metabolic gene expression signatures resemble chronic aerobic training. But every single result is preclinical. Zero human RCTs exist as of 2026-04. Effect sizes in humans are unknown.
Breadth of benefits (4.0/5.0). Activates ERR-alpha, beta, and gamma simultaneously β hits mitochondrial biogenesis, fatty acid oxidation, slow-twitch fiber conversion, and hepatic lipid handling. Broad mechanism, broad theoretical reach. Mouse data supports benefits across endurance, fat loss, glucose handling, and hepatic steatosis.
Evidence quality (2.0/5.0). Thomas Burris lab is credible (the original ERR-beta agonist work). But this is entirely mouse and rat data. No Cochrane review, no meta-analysis, no human pharmacokinetics, no MTD, no long-term safety. Industry-independent replication is minimal. This is research chemistry, not clinical evidence.
Speed of onset (4.0/5.0). Mouse endurance benefits appear within 8 days. Gene expression changes in hours. IF the drug translates to humans, onset would likely be fast relative to training adaptations.
Durability (2.0/5.0). Effects appear to fade quickly after discontinuation in the mouse models. Not a one-and-done intervention.
Bioindividuality upside (3.0/5.0). Unknown in humans. In theory the mechanism is universal but we do not have data on responder profiles, genetic variants, or baseline-dependent effects.
Downside (4.17 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 4.0 | 1.200 | |
| Side Effect Profile | 15% | 2.5 | 0.375 | |
| Financial Cost | 5% | 3.0 | 0.150 | |
| Time/Effort Burden | 5% | 2.5 | 0.125 | |
| Opportunity Cost | 5% | 2.5 | 0.125 | |
| Dependency / Withdrawal | 15% | 2.5 | 0.375 | |
| Reversibility | 25% | 2.5 | 0.625 | |
| Total | 2.975 | |||
| Γ 1.4 (risk asymmetry) | 4.165 |
Downside Rationale
Safety risk (4.0/5.0). Zero human safety data. No MTD, no long-term exposure studies, no drug interaction profile. Unknown off-target effects. This is the dominant downside.
Side effect profile (2.5/5.0). Mouse data shows mild transient effects. Unknown in humans.
Financial cost (3.0/5.0). Research chemistry market pricing β roughly $100-300/month for a typical dose.
Time/effort burden (2.5/5.0). Injection or sublingual protocol, requires planning.
Opportunity cost (2.5/5.0). Time and budget could go toward proven exercise protocols with known safety profile.
Dependency/withdrawal (2.5/5.0). No data either way.
Reversibility (2.5/5.0). Likely reversible based on mouse washout data, but unknown in humans.
Verdict
β Best for: Advanced biohackers with medical supervision, research scientists tracking exercise mimetics, people with metabolic conditions who have exhausted conventional options and are willing to accept preclinical-only evidence.
β Avoid if: You want any human clinical evidence, you are under 25, you are pregnant or nursing, you have any cardiovascular condition, you take any medication, or you expect legal regulatory status to protect you (this is a research compound with no approved human use).
Key Evidence Sources
- Billon C et al. 2023. Synthetic ERRΞ±/Ξ²/Ξ³ agonist alleviates metabolic syndrome β Original Burris lab paper demonstrating endurance and metabolic improvements in mice
- Nature 2023 news coverage β Exercise in a pill? β Journalistic overview of the Burris lab findings
- PubChem CID 146025 β Chemical structure, known properties
Other interventions for Cardiovascular
See all ratings βπ How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0β10 score. 5.0 is neutral (benefits and risks balance). Above 5 = benefits outweigh risks; below 5 = risks outweigh benefits. Every downside dimension is multiplied by 1.4 before subtraction because harm potential is more consequential than benefit potential β the precautionary principle encoded as math.
Upside: 3.030 / 5.00
Downside (post-1.4Γ): 4.170 / 5.00
EV = -1.140
Score = ((EV + 7) / 12) Γ 10 = 4.9 / 10
